publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
enter
protozo
infect
commonest
caus
diarrhoea
hivseroposit
person
tabl
associ
apoptosi
occasion
crypt
abscess
much
sever
villu
atrophi
seen
hiv
infect
alon
malabsorpt
maldigest
increas
bowel
frequenc
howev
symptom
persist
despit
morbid
mortal
late
aid
associ
gastrointestin
diseas
whilst
oesophag
candidosi
respond
readili
treatment
cytomegaloviru
enter
may
clear
antivir
agent
two
commonest
protozo
pathogensmicrosporidia
cryptosporidia
erad
protozoa
caus
disrupt
smallbowel
villu
architectur
unknown
mechan
sever
malabsorpt
maldigest
diarrhoea
weight
loss
major
contributor
death
patient
aid
commonli
caus
protozo
gut
infect
host
metabol
respons
infect
typic
starvat
patient
like
respond
provis
addit
calori
ideal
enter
rout
contrast
weight
loss
associ
opportunist
infectionsmycobacterium
avium
intracellular
cytomegalovirusi
characteris
cachexia
unlik
respond
simpl
refeed
commonest
caus
oesophag
symptom
candidosi
odynophagia
dysphagia
oral
candidosi
aidsdefin
diagnosi
treat
empir
system
azol
second
frequent
caus
cytomegaloviru
cmv
produc
either
diffus
oesophag
discret
ulcer
aetiolog
lesion
confirm
biopsi
centr
ulcer
area
detect
cmv
inclus
bodi
enhanc
immunoperoxidas
stain
oesophagoscopi
occasion
reveal
vesicl
typic
herp
simplex
oesophag
diagnos
either
biopsi
smear
brush
show
typic
giant
cell
mani
oesophag
ulcer
lead
dysphagia
idiopath
possibl
caus
unknown
opportunist
virus
hiv
ulcer
may
respond
thalidomid
pathogenesi
hiv
initi
believ
caus
intestin
symptom
sinc
hivseroposit
individu
free
intestin
pathogen
commonli
diarrhoea
howev
frequenc
pathogenneg
diarrhoea
depend
extent
diagnost
investig
definit
diarrhoea
prospect
studi
pathogenneg
diarrhoea
followup
reveal
unsuspect
pathogen
minor
patient
lowvolum
diarrhoea
either
resolv
spontan
control
antimotil
agent
respons
accord
featur
irrit
bowel
syndrom
hivseroposit
person
free
intestin
pathogen
minor
abnorm
villu
architectur
characterist
mild
villu
atrophi
associ
either
crypt
hypoplasia
hyperplasia
minor
abnorm
unlik
caus
diarrhoea
sinc
occur
symptomfre
individu
associ
either
mild
malabsorpt
carbohydr
howev
consist
increas
smallbowel
permeabl
hivseroposit
individu
function
abnorm
minor
structur
abnorm
small
bowel
mucosa
may
due
immunolog
chang
produc
hiv
infect
lamina
propria
lymphocyt
activ
cell
caus
villu
atrophi
fetal
gut
explant
hiv
caus
activ
cell
hiv
identifi
lamina
propria
larg
small
intestin
detect
quantif
relat
diarrhoea
whether
hiv
also
infect
smallbowel
mucos
cell
initi
shown
insitu
hybridis
unknown
possibl
mechan
villu
damag
includ
ingress
foreign
antigen
increas
permeabl
set
motion
viciou
circl
releas
cytokin
inflammatori
mediat
altern
bacteri
overgrowth
small
intestin
hivseroposit
patient
report
small
studi
might
produc
inflammatori
respons
villu
atrophi
bacteri
overgrowth
might
occur
hypochlorhydria
report
aid
patient
hypochlorhydria
common
starvat
system
infect
may
therefor
occur
advanc
aid
without
hivinduc
defect
gastric
secret
neither
hypochlorhydria
bacteri
overgrowth
univers
find
patient
advanc
hiv
infect
mechan
unlik
import
role
villu
atrophi
harrow
pictur
emaci
termin
ill
aid
patient
remind
lack
understand
immunolog
mechan
normal
control
opportunist
infect
mani
gastrointestin
pathogen
patient
aid
resist
treatment
lead
inexor
weight
loss
death
although
knowledg
pathogenesi
clinic
signific
weight
loss
improv
consider
yet
led
sustain
effort
improv
nutrit
statu
earli
stage
diseas
fluoresc
agent
calcofluor
therebi
provid
excel
screen
test
result
confirm
giemsa
stain
cryptosporidia
stool
diagnos
modifi
ziehlneelsen
auramin
stain
enter
bacteria
usual
detect
routin
stool
cultur
occasion
found
blood
stool
cultur
mycobacterium
avium
intracellular
tediou
uncertain
pathogen
signific
sinc
colonis
occur
without
diarrhoea
valu
stool
electron
microscopi
enterovirus
debat
sinc
studi
organ
similar
preval
individu
solid
stool
diarrhoea
detect
limit
valu
enterovirus
produc
selflimit
infect
even
hivseroposit
person
untreat
mucos
biopsi
although
diagnosi
stool
analysi
alon
suggest
johanson
sonnenberg
studi
may
overestim
valu
symptomat
treatment
ignor
possibl
cytomegaloviru
infect
sometim
respond
therapi
gut
biopsi
way
diagnos
infect
cmv
adenoviru
infect
commonli
found
larg
intestin
sigmoidoscopi
rectal
biopsi
probabl
best
initi
invas
gastroenterolog
investig
patient
diarrhoea
case
cmv
coliti
affect
right
side
colon
small
intestin
colonoscopi
smallintestin
biopsi
may
indic
individu
persist
diarrhoea
neg
rectal
biopsi
starvat
diarrhoea
often
proport
mucos
abnorm
secretori
compon
like
secretori
respons
shown
isol
segment
human
jejunum
expos
faec
calv
infect
cryptosporidia
patient
moder
increas
stool
volum
due
cryptosporidiosi
decreas
intestin
transit
time
may
exacerb
diarrhoea
protozo
infect
whether
primari
motil
defect
consequ
malabsorpt
enter
nerv
damag
unclear
anoth
possibl
motil
chang
nerv
damag
mediat
nitric
oxid
releas
result
stimul
nitric
oxid
synthas
macrophag
infect
hiv
opportunist
organ
possibl
remain
unexplor
chang
immunolog
respons
gut
mucosa
allow
persist
protozo
infect
hivseroposit
individu
abnorm
immun
respons
may
import
pathogenesi
diarrhoea
lymphocyt
popul
lamina
propria
hivseroposit
patient
show
disproportion
reduct
compar
circul
count
experi
immunocompromis
mice
shown
cell
essenti
erad
cryptosporidia
respons
may
import
control
infect
mice
interferongamma
releas
macrophag
may
also
role
alter
macrophag
respons
hivseroposit
individu
unabl
mount
respons
cryptosporidi
infect
may
lead
aberr
cytokin
releas
consquent
intestin
damag
increas
concentr
tumour
necrosi
factoralpha
report
faec
mucosa
patient
protozo
diarrhoea
studi
complex
balanc
variou
cytokin
tissu
receptor
await
stool
analysi
initi
investig
hivseroposit
subject
diarrhoea
three
sampl
identifi
pathogen
cryptosporidia
may
alway
take
appropri
stain
stool
infect
diagnos
histolog
examin
small
larg
bowel
biopsi
specimen
histolog
examin
duoden
biopsi
specimen
may
also
reveal
previous
unsuspect
microsporidia
giardia
avium
intracellular
isospora
ultrastructur
examin
enter
biopsi
specimen
electromicroscopi
done
routin
enabl
speciat
organ
microsporidia
mayb
use
addit
light
microscopi
figur
analysi
six
stool
sampl
histolog
examin
small
larg
bowel
biopsi
speicmen
detect
infecti
caus
diarrhoea
hivseroposit
individu
individu
pathogen
found
initi
investig
minor
symptom
usual
resolv
spontan
continu
largevolum
diarrhoea
widespread
kaposi
sarcoma
gut
lymphoma
subsequ
diagnos
stool
analysi
acut
ill
individu
diarrhoea
treat
ciprofloxacin
enter
bacteria
hivseroposit
individu
sensit
chronic
diarrhoea
antimotil
agent
reduc
symptom
oral
rehydr
therapi
may
also
import
maintain
electrolyt
balanc
somatostatin
analogu
octreotid
vapreotid
use
hivseroposit
individu
diarrhoea
motil
effect
possibl
hiv
aminoacid
sequenc
similar
vasoact
intestin
peptid
vip
may
induc
diarrhoea
upregul
vip
receptor
increas
concentr
vip
shown
patient
pathogenneg
diarrhoea
octreotid
likewis
success
somatostatin
analogu
effect
pathogenneg
diarrhoea
less
protozo
diarrhoea
one
placebocontrol
studi
show
effect
expens
agent
unlik
wide
role
treatment
hivrel
diarrhoea
microsporidiosi
two
genera
microsporidia
associ
diarrhoea
enterocytozoon
bieneusi
found
human
be
known
effect
treatment
although
uncontrol
studi
suggest
patient
may
respond
albendazol
thalidomid
atovaquon
encephalitozoon
spp
much
less
commonli
associ
diarrhoea
infect
organ
also
caus
dissemin
diseas
organ
erad
albendazol
resolut
symptom
cryptosporidiosi
mani
anecdot
report
treatment
cryptosporidiosi
difficult
interpret
view
variabl
natur
histori
infect
least
third
patient
diarrhoea
resolv
spontan
especi
initi
count
investig
suitabl
therapeut
agent
hamper
inabl
cultur
organ
vitro
major
differ
anim
model
human
infect
although
mani
agent
use
one
proven
efficaci
paromomycin
reduc
stool
volum
quantit
stool
analys
shown
reduct
oocyst
excret
therapi
organ
seldom
erad
therapi
infect
difficult
primari
prophylaxi
would
highli
desir
goal
human
cryptosporidiosi
waterborn
infect
sinc
minimum
infecti
dose
lowbetween
one
five
oocyst
gnotobiot
anim
oocyst
healthi
human
be
standard
screen
test
metropolitan
water
suppli
may
sensit
enough
detect
boil
water
elimin
infect
oocyst
strategi
sensibl
hivseroposit
patient
count
less
enter
treatment
cytomegaloviru
enter
remain
controversi
ganciclovir
foscarnet
reduc
symptom
improv
macroscop
microscop
appear
colon
week
therapi
howev
relaps
median
time
week
common
initi
treatment
decis
give
mainten
therapi
therefor
depend
initi
sever
symptom
sinc
diagnosi
cytomegaloviru
enter
improv
patient
milder
symptom
detect
qualiti
life
treatmentanticmv
agent
given
intraven
consider
toxicitymay
enhanc
compar
therapi
whether
patient
left
untreat
develop
complic
cmv
enter
toxic
dilat
perfor
common
earli
year
epidem
remain
determin
oral
ganciclovir
high
dose
overcom
problem
bioavail
may
limit
role
primari
prophylaxi
prevent
develop
cmv
diseas
nevertheless
therapi
major
toxic
limit
benefit
extrem
expens
widespread
use
primari
prophylaxi
must
await
develop
effect
agent
marker
allow
better
predict
patient
like
develop
cmv
diseas
mycobacterium
aviumintracellular
mai
sever
immunosuppress
hivseroposit
patient
maiinduc
diarrhoea
primari
prophylaxi
rifabutin
clarithromycin
may
reduc
incid
mai
establish
smallbowel
infect
necessit
treatment
convent
quadrupl
therapi
treatment
must
includ
effect
agentsclarithromycin
azithromycin
resist
drug
probabl
limit
addit
rifabutin
efficaci
improv
ethambutol
weight
loss
common
featur
late
hiv
infect
initi
wast
thought
featur
hiv
infect
per
se
howev
although
slight
increas
rest
energi
expenditur
ree
individu
level
immunosuppress
weight
lean
bodi
mass
normal
unless
opportunist
infect
superven
pattern
weight
loss
characterist
starvat
decreas
ree
rel
preserv
lean
bodi
mass
seen
enter
protozo
infect
starvat
respons
probabl
caus
combin
voluntari
reduct
intak
reduc
diarrhoea
anorexia
relat
malabsorpt
certain
opportunist
infect
especi
avium
intracellular
cmv
produc
cachect
respons
ree
rais
pronounc
loss
lean
bodi
mass
like
relat
inappropri
cytokin
releas
although
increas
fat
mass
may
improv
bodi
imag
replet
lean
bodi
mass
probabl
requir
improv
locomotor
function
mani
aspect
qualiti
life
hivseroposit
individu
lose
weight
starvat
like
respond
food
supplement
given
oral
parenter
enter
via
nasogastr
tube
percutan
gastroenterostomi
tube
patient
may
also
benefit
appetit
stimul
howev
refeed
like
ineffect
cachexia
may
improv
lean
bodi
mass
respons
anabol
agent
eg
recombin
human
growth
hormon
abdomin
pain
cmv
infect
associ
arter
consequ
ischaemia
may
associ
acalcul
cholecyst
append
cmv
coliti
commonli
give
rise
abdomin
pain
bloodi
diarrhoea
rebound
tender
origin
abdomin
pain
uniqu
hivseroposit
patient
aidsrel
scleros
cholang
caus
variou
opportunist
includ
microsporidia
cmv
cryptosporidia
condit
associ
sclerosi
intrins
extrins
hepat
system
chang
pancreat
duct
scleros
cholang
may
also
common
without
pain
usual
discomfort
lead
investig
sinc
natur
histori
pain
variabl
frequent
sphincterotomi
improv
symptom
unclear
background
low
adher
patient
prescrib
selfadminist
medic
intervent
ubiquit
low
adher
limit
benefit
current
medic
care
effort
assist
patient
follow
treatment
might
improv
effici
care
substanti
enhanc
benefit
object
summaris
result
randomis
control
trial
rct
intervent
help
patient
follow
prescript
medic
method
previou
systemat
review
updat
computeris
search
medlin
intern
pharmaceut
abstract
psychinfo
hstar
onlin
databas
bibliographi
articl
patient
adher
articl
review
person
collect
contact
author
articl
judg
interest
report
origin
data
concern
unconfound
rct
intervent
improv
adher
prescrib
medic
one
measur
medic
adher
one
measur
treatment
outcom
least
followup
group
studi
longterm
treatment
least
month
followup
studi
posit
initi
find
inform
studi
design
featur
intervent
control
find
ex
tract
one
review
rk
check
two
review
find
relev
citat
abstract
screen
full
text
articl
review
detail
rct
met
criteria
studi
dispar
clinic
problem
adher
intervent
measur
report
adher
clinic
outcom
studi
warrant
metaanalysi
seven
intervent
associ
improv
adher
six
intervent
led
improv
treatment
outcom
shortterm
treatment
one
studi
show
effect
adher
outcom
counsel
w
ritten
inform
intervent
effect
longterm
care
complex
includ
variou
combin
conveni
care
inform
counsel
remind
selfmonitor
reinforc
famili
therapi
form
addit
supervis
attent
even
effect
intervent
lead
substanti
improv
adher
interpret
although
adher
treatment
outcom
improv
certainusu
complexintervent
full
benefit
medic
realis
current
achiev
level
adher
time
addit
effort
direct
toward
develop
test
innov
approach
assist
patient
follow
treatment
prescript
lancet
introduct
nonadher
prescrib
treatment
common
typic
adher
rate
prescrib
medic
rang
extent
treatment
respons
relat
dose
nonadher
reduc
treatment
benefit
bia
assess
efficaci
treatment
increas
number
efficaci
selfadminist
treatment
need
appar
better
understand
manag
nonadher
previou
review
examn
accuraci
clinic
measur
nonadher
intervent
improv
attend
appoint
medic
servic
intervent
enhanc
medic
adher
last
review
includ
trial
